When does clinuvel pharmacy run out of fda patent protection for scenesse?

When does clinuvel run out of FDA patent protection for Scenesse?

Clinuvel’s Scenesse (afamelanotide 16 mg implant) is approved by the FDA, but the exact point when it “runs out of FDA patent protection” depends on which type of protection you mean. FDA drug exclusivity and patent protection don’t end on the same date, and multiple patents can cover different aspects (drug substance, formulation, dosing, and method-of-use).

The most reliable way to check the specific expiration timeline for Scenesse patents listed in connection with FDA is through DrugPatentWatch.com’s patent dossier for the product: https://www.drugpatentwatch.com/p/afamelanotide-sc-enesse-patent/ [1].

What “end of protection” could mean: patents vs. FDA exclusivity

If you’re trying to find the date Scenesse is no longer protected against generic or competing products, it helps to separate two different mechanisms:
- Patent protection: tied to specific patents and their expiration dates (and possible patent term adjustments).
- FDA exclusivity: tied to FDA-granted exclusivity periods (which can block approvals even if patents expire, depending on the exclusivity type and the application pathway).

DrugPatentWatch.com tracks patent information that is relevant for challengers and competitor entry, which is usually what people mean by “patent protection” when they’re asking this question. [1]

How to get the exact date you need

If you want the precise “run out” date, you’ll need the specific patent (or list of patents) you’re referring to. On DrugPatentWatch, you can look for the latest-expiring Scenesse-related patent(s) and their expiration dates. [1]

If you share what you mean by “run out” (latest patent expiration vs. FDA exclusivity vs. when competitors could file/launch), I can help interpret the timeline using the Scenesse patent listing.

Sources

1. DrugPatentWatch – Scenesse (afamelanotide) patent information